Today: 28 February 2026
Subscribe
Browse Category

NYSE:LLY 12 January 2026 - 17 January 2026

Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

Eli Lilly shares rose 0.5% in after-hours trading after the FDA delayed its decision on the company’s obesity drug orforglipron to April 10. Lilly and Novo Nordisk face a lawsuit from Texas-based Strive Specialties, which alleges both companies restricted access to cheaper compounded versions of GLP-1 drugs. Lilly also disclosed a 10% stake in Aktis Oncology.
17 January 2026
··
Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

Eli Lilly shares fell 3.8% premarket to $1,033 after FDA documents set an April 10 decision date for its weight-loss pill under a fast-track program. Strive Specialties sued Lilly and Novo Nordisk in Texas, alleging efforts to block cheaper compounded GLP-1 drugs. Novo Nordisk shares dropped 3%. Investors await further FDA guidance and Lilly’s Feb. 4 earnings call.
16 January 2026
··
Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

Eli Lilly shares fell 3.8% to $1,032.97 in after-hours trading after the FDA delayed its decision on the company’s obesity pill to April 10. A Texas compounding pharmacy filed a new lawsuit against Lilly and Novo Nordisk, alleging efforts to block access to cheaper alternatives. Investors are watching Lilly’s Feb. 4 earnings call and the FDA’s April decision as key dates.
15 January 2026
··
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer shares fell 0.6% to $25.42 in late-morning trading Thursday as U.S. vaccine policy changes fueled uncertainty. Sanofi warned of weaker U.S. vaccine demand; Pfizer’s CEO criticized the new recommendations. Moderna and Merck also traded lower. Investors await Pfizer’s Feb. 3 results for updates on 2026 outlook and new product pipeline.
15 January 2026
········
Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10

Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10

Eli Lilly shares fell 4.7% to $1,022.50 after Reuters reported the FDA delayed its decision on the company’s experimental weight-loss pill to April 10. Strive Specialties sued Lilly and Novo Nordisk in Texas, alleging anticompetitive practices tied to GLP-1 drugs. Novo Nordisk shares dropped 3.6%. Investors await Lilly’s Feb. 4 earnings for updates on the pill’s timeline and legal risks.
15 January 2026
·
Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

Eli Lilly shares fell about 0.3% in after-hours trading Wednesday after the FDA asked drugmakers to remove suicide-risk warnings from GLP-1 weight-loss drugs. The agency found no link between the drugs and increased suicide risk. Investors are watching Lilly’s plans for its oral obesity drug, orforglipron, which could launch soon at a $150 monthly price.
15 January 2026
··
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics (GPCR) shares surged 7.5% to $83.76 Wednesday on over 1 million shares traded, fueled by buyout speculation and renewed interest in oral obesity drugs. Novo Nordisk executives signaled openness to acquisitions, while Structure reported Phase 2b data showing its oral GLP-1 drug aleniglipron led to 11.3% placebo-adjusted weight loss at 36 weeks. Viking Therapeutics and Terns Pharmaceuticals also rose sharply.
14 January 2026
······
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer shares rose 1.4% to $25.51 Wednesday morning, outpacing a broader market decline. CEO Albert Bourla said the company misjudged the cash-pay obesity drug market and plans about 10 Phase 3 obesity trials in 2026. Investors are watching for Feb. 3 results and updates on late-stage trial launches. Pfizer expects no revenue growth before 2029 as it faces major patent expirations.
14 January 2026
·····
Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next

Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next

Eli Lilly shares fell about 0.4% Wednesday after the FDA ordered drugmakers to remove suicidality warnings from obesity drugs including Zepbound. The FDA said its review found no increased risk of suicidal thoughts with GLP-1 drugs. Investors are watching for updates on Lilly’s oral obesity pill ahead of the Feb. 4 earnings call.
14 January 2026
···
Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

Eli Lilly shares fell 0.4% after hours to $1,077.19 as the FDA told drugmakers to remove suicide warnings from GLP-1 weight-loss drugs, including Lilly’s Zepbound. At the JPMorgan Healthcare Conference, Lilly and rivals pitched new obesity pills and longer-acting shots, with Lilly targeting a second-quarter U.S. approval for its oral drug. Amgen and Novo Nordisk highlighted new data and launches in the crowded obesity market.
14 January 2026
··
Nvidia stock stays flat after China tightens H200 chip approvals; Eli Lilly $1B AI lab grabs attention

Nvidia stock stays flat after China tightens H200 chip approvals; Eli Lilly $1B AI lab grabs attention

Nvidia shares slipped 0.04% to $184.87 after hours Tuesday following reports China is restricting approvals for H200 AI chip purchases. Nvidia denied requiring upfront payment from Chinese buyers. The company also announced a $1 billion healthcare AI lab with Eli Lilly and new partnerships, but traders remain focused on China’s impact on chip demand.
13 January 2026
···
Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Eli Lilly shares rose 0.2% after the FDA asked drugmakers to remove suicide-related warnings from GLP-1 weight-loss drugs. Lilly’s R&D chief said the company plans a rapid global launch of its oral obesity drug orforglipron, priced at $150 a month. Investors are watching for increased pill competition and the FDA’s upcoming decision.
13 January 2026
···
Nvidia stock barely budges after H200 China payment reset; Lilly AI lab plan in focus

Nvidia stock barely budges after H200 China payment reset; Lilly AI lab plan in focus

Nvidia said it will not require upfront payment for H200 AI chips, countering reports of stricter terms for Chinese buyers. Shares edged up 0.03% to $184.94 in early New York trading. Investors remain focused on China sales and the company’s Feb. 25 earnings for updates on demand and margins. Chip sector peers posted mixed results as U.S. inflation data met forecasts.
13 January 2026
····
Nvidia stock in premarket: H200 China payment clarification, Lilly AI lab and TSMC earnings in focus

Nvidia stock in premarket: H200 China payment clarification, Lilly AI lab and TSMC earnings in focus

Nvidia shares were flat in premarket trading after the company said customers in China won’t need to pay upfront for its H200 AI chips. Nvidia and Eli Lilly announced a $1 billion, five-year partnership to build an AI drug research lab in the Bay Area. Chip stocks rose, with Taiwan Semiconductor up nearly 2.5% ahead of its Jan. 15 earnings report.
13 January 2026
·····
Nvidia stock barely moves after hours as $1 billion Eli Lilly AI lab plan lands

Nvidia stock barely moves after hours as $1 billion Eli Lilly AI lab plan lands

Nvidia and Eli Lilly will invest up to $1 billion over five years in a joint AI drug discovery lab in the San Francisco Bay area, using Nvidia’s latest chips. Nvidia shares closed at $184.88, up 0.01%, and hovered near $184.94 after hours. The exact lab location will be announced in March. Investors are watching TSMC’s earnings report on January 15 and Nvidia’s on February 25.
12 January 2026
···
Nvidia stock gains on Eli Lilly $1 billion AI lab plan as traders eye TSMC, earnings

Nvidia stock gains on Eli Lilly $1 billion AI lab plan as traders eye TSMC, earnings

Nvidia and Eli Lilly will invest up to $1 billion in a Bay Area AI drug discovery lab over five years, sending Nvidia shares up 0.8% to $186.37 and Lilly up 0.2% to $1,066.14. AMD, Broadcom, and TSMC also rose as AI-focused stocks lifted the Nasdaq. TSMC reports earnings Jan. 15, with analysts expecting a 27% Q4 profit jump on AI chip demand. Nvidia’s next earnings are due Feb. 25.
12 January 2026
···
Nvidia stock wobbles after $1B Eli Lilly AI lab plan as CPI and TSMC loom

Nvidia stock wobbles after $1B Eli Lilly AI lab plan as CPI and TSMC loom

Nvidia and Eli Lilly will invest $1 billion over five years in a joint research lab in the San Francisco Bay Area, aiming to use Nvidia’s new AI chips to accelerate drug discovery. Nvidia shares slipped 0.2% to $184.42 by 10:30 a.m. ET. Thermo Fisher Scientific will also collaborate with Nvidia on lab automation. The new site is expected to open by the end of March.
12 January 2026
····
Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly shares rose about 0.7% Monday after announcing a $1 billion, five-year AI drug discovery lab partnership with Nvidia. The Bay Area facility, using Nvidia’s Vera Rubin chips, will open in March with teams from both firms. Investors are watching for updates from CEO David Ricks at the J.P. Morgan Healthcare Conference on Tuesday and Lilly’s earnings call on Feb. 4.
12 January 2026
······
1 2 3 4 5 6 … 12
Go toTop